Oser Communications Group

Chain Drug Store Annual Meeting Apr 26 2015

Issue link: http://osercommunicationsgroup.uberflip.com/i/499812

Contents of this Issue

Navigation

Page 13 of 31

C h a i n D r u g s t o r e D a i l y S u n d a y, A p r i l 2 6 , 2 0 1 5 1 4 CAMBER PHARMACUETICALS NAMED "SUPPLIER OF THE YEAR" BY ANDA, INC. Camber Pharmaceuticals is pleased to announce its selection as a 2014 "Supplier of the Year" at Anda's annual Supplier Strategy Meeting in Doral, Fla. The award is the result of a survey con- ducted by an independent third party to evaluate a variety of metrics considered critical to effective partnering by key Anda employees. "We are very proud to have been named Anda's Supplier of the Year," commented Kon Ostaficiuk, President of Camber. "This award exemplifies our commitment to providing our partners with outstanding quality, service and consistent supply. It also helps to be working with an extraordinary team of dedicated professionals at Anda who truly embrace the meaning of partner- ship." Anda's recently retired President, Al Paonessa III, presented the award to Camber National Account Manager, Clayton Smith, say- ing that Anda has truly attempted to make "partnership" more than a buzz- word, but a way of doing business. Commented Smith: "Anda's exceptional commitment to partnership is evident, and it's very exciting to be recognized by them. I'm extremely pleased to accept the award on behalf of Camber." Established in 1992, Anda provides customers with industry-leading cus- tomer service, competitive pricing and stocks more than 11,000 products direct from 300-plus brand and generic manufacturers. Camber's commitment to its customers is to bring the highest quality generic pharmaceuticals to the market. Camber's product strategy is simple – capitalize on core strengths to deliver maxi- mum profitability to customers by lever- aging a flexible corporate structure, pro- viding a broad product line and maintain- ing an unwavering commitment to quali- ty, value and service. Visit Camber at booth #534. For more information, contact Megan Becker at 732.529.0436 or mbecker@camber pharma.com. ROXANE FOCUSED ON KEEPING PRODUCT LINE AFFORDABLE AND AVAILABLE Behind every Roxane product, you'll find a team that connects you to the peo- ple who work tirelessly to bring econom- ical generic pharmaceuticals to patients everywhere. With continual advances in cutting-edge administration and dosage for more than 100 medications, and ongoing efforts to keep the product line affordable and available to as many cus- tomers as possible, the team at Roxane Laboratories is laser focused on meeting and exceeding the needs of each and every one of its customers and patients. Roxane Laboratories operates as the research and development and sales and marketing arms of Boehringer Ingelheim's multi-source pharmaceutical business. Today, Roxane markets more than 100 medications in 280 package sizes. Roxane is committed to expand its line of multisource pharmaceutical prod- ucts that are formatted as bulk and unit- dose package configurations for liquids and solids; coated, sustain-released and controlled-release tablets; nasal sprays; topical solutions; cytotoxics and CII nar- cotics. Advancements in controlled sub- stances, sustain-released items, potent compounds, unit doses and bulk packag- ing all reflect its dedication to provide customers with innovative, technically complex products from its FDA- approved facilities. The team at Roxane understands how every aspect of its business can affect your patients' lives – everything from answered phones calls to correct shipments and efficient manufacturing processes. It strives for excellence with every customer experience and is com- mitted to provide quality products for a range of clinical areas. Roxane also rec- ognizes that growth and development in its product lines impacts patients everywhere; its team contains highly skilled researchers who are constantly working to expand the number of its generic pharmaceuticals. These scientists, combined with its patent-experienced attorneys and pur- chasing team, are tasked with putting more affordable generic treatments on the market and into your hands as soon as possible. Its award-winning pursuit of high- quality products and service is also accompanied by a lean manufacturing model staffed by a skilled, flexible work- force. This innovative manufacturing and business practice allows for quick shifts in production based on marketing oppor- tunities and business needs. As always, Roxane maintains impressive levels of safety, quality and compliance. To meet the changing needs of its patients, Roxane has continued to grow its product lines to offer a variety of treatment options. To accommodate this growth, it expanded its Wilson Road facility in Central Ohio by adding a 105,000- square-foot complex in 2011. Like all of its efficient operations, this facility meets the rigorous design standards required for safe and compliant manufacturing. Quality, safe and affordable growth has continued for Roxane in 2013 and 2014. Roxane is proud to have launched these seven new generic products, including Cevimeline Hydrochloride Capsules, Oxycodone Hydrochloride Oral Solution USP, CII, Telmisartan Tablets USP, Telmisartan and Hydrochlorothiazide Tablets USP, Eszopiclone Tablets, CIV, Cyclophosphamide Capsules and Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets, CII. For more information, visit roxane.com. NACDS EVENTS APP ENHANCES ANNUAL MEETING EXPERIENCE Introducing its latest resource for meet- ing and conference attendees, the National Association of Chain Drug Stores (NACDS) now has a "NACDS Events" mobile application. A multi- event shell, the app offers navigational tools and resources to enhance the attendee and exhibitor experience at NACDS meetings and conferences, including the 2015 NACDS Annual Meeting. The 2015 NACDS Annual Meeting is taking place April 25-28 in Palm Beach, Florida. The meeting offers a unique opportunity for more than 2,000 of today's most influential retail execu- tives from drug, food and mass merchan- dising and their supplier partners to share insights, and build relationships that extend far beyond the four-day meeting. The robust 2015 NACDS Annual Meeting dashboard within the mobile app provides attendees the tools to create a personalized schedule for the meeting, browse speakers and bookmark sessions of interest, search for exhibitors, refer- ence resources in the local area, and access social media to keep up with updates and the "buzz" surrounding the meeting. One of the features that is sure to be beneficial is the interactive floor plan, which will enable Annual Meeting atten- dees to search the locations of companies they may wish to meet with during the meeting. This "NACDS Events" mobile app can be downloaded on a number of mobile platforms. Once the mobile app is downloaded, subscribers are directed to download the 2015 NACDS Annual Meeting dashboard. "NACDS continues to utilize tech- nology to enhance the experience for meeting attendees. This mobile resource will provide attendees practi- cal tools to assist in advanced planning and onsite implementation - right at their fingertips," said NACDS President and CEO Steven C. Anderson, IOM, CAE. "Innovations in technology enable NACDS to bring cutting-edge efficiencies to its member programs and services." NOVARAX APPOINTS BRIAN ROSEN AS VICE PRESIDENT, GOVERNMENT AFFAIRS Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, has announced the appoint- ment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. His efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent sea- sonal and pandemic influenza vaccine candidates. Rosen comes to Novavax with over 20 years of industry and patient advo- cacy experience, the vast majority of which he spent engaged in government affairs, advocacy, reimbursement and policy work. He was most recently the Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide. He previously developed and ran the Government Affairs, Policy and Alliance Development functions for MedImmune, which developed Synagis, a monoclonal antibody used to prevent RSV disease in premature new- borns, and FluMist, a live attenuated influenza vaccine. "The healthcare landscape is con- stantly changing and supportive vaccine policy requires diligent attention and coordination in concert with Novavax's commercialization plans. Brian's exten- sive experience, particularly with RSV and influenza, is critical to planning and executing a commercial launch of our vaccines," said John Trizzino, Novavax Senior Vice President, Commercial Operations. "Brian is a key addition to our management team and brings valu- able perspective that I am confident will contribute to bringing our novel vaccines to market."

Articles in this issue

Links on this page

view archives of Oser Communications Group - Chain Drug Store Annual Meeting Apr 26 2015